Screening for cancer consists of the identification of preclinical disease by a relatively simple test. The objective of screening is to reduce the risk of deaththat is mortality from cancer subjected to screening. For cervical cancer the screening test is aimed at detecting preinvasive lesions. Therefore, the reduction in the incidence of invasive disease is also the objective of screening for cervical cancer, and the indicator for the effect is a change of incidence in the time before and after application of the screening test or a difference in incidence between those subjected to screening and those not subjected to screening. The screening programme has also other effects which are related to quality of life of the target population or to the economic consequences. Many of them are adverse and there is a need to find a balance between the benefits and the harms. No unique solution exists but any programme is a result of value judgment in weighing between the benefits and harms.
A prerequisite for a successful programme is a valid screening test. The cytological smear is highly sensitive and specific for cervical intraepithelial neoplasia. However, reducing the risk of death from cancer in a population does not depend on the screening test only, but rather on the total programme'. Therefore, the total programme should have sufficient validity. This assumes, in addition to the validity of the test, that: the target population is adequately identified and covered; the individuals in the population are identified and encouraged to attend the programme; there are adequate field facilities for taking smears in addition to an adequate laboratory; there are adequate facilities for diagnostic confirmation and treatment; there is a carefully designed and agreed referral system. These prerequisites show that the emphasis must be placed on the organization of a screening programme. the municipal authorities. According to the recommendation of the Cancer Society of Finland, the screening interval is five years. During the early years of the programme the cohorts aged 40, 45 and 50 were screened most intensively. Later the cohorts aged 30, 35 and 55 were also frequently screened, and sometimes the programme covers an even wider age range, depending on the municipality. The Cancer Society of Finland recommended the ages from 30 to 55 to be screened and since 1987 the cohort of 60 years was also included in the recommendation.
The Nordic countries have different cervical cancer screening policies within the organized programmes. In Iceland" and Sweden", as in Finland, a nationwide population based organized programme has been in operation at least since the early 1970s. The recommended age groups to be covered were 25-69 years in Iceland and 30-49 years in Sweden. The screening intervals recommended are 2-3 years in Iceland and 4 years in Sweden. In Denmark's" the recommendations vary by county and in Norway? only 5% of the population was covered by an organized programme. Cytological smears are, however, frequently also taken outside the organized system, by private gynaecologists and elsewhere. Such smears are taken more frequently than the smears in the organized programmes in all the Nordic countries except in Iceland.
Effect of the programme on the risk of cervical cancer
In Finland about 400 new cases of cervical cancer were diagnosed annually before the establishment of the screening programme ( Figure 1 ). Since the early 1980s the annual number has been less than 200. Also, the changes in the incidence of invasive cervical cancer by age correlated with the intensity of the screening programme. The reduction in age-specific Organized programmes in the Nordic countries In Finland as well as in most of the other Nordic countries there is an organized nationwide screening programme for cervical cancer-which fulfil the general prerequisites and makes it possible to follow up each woman for the occurrence of intraepithelial cervical neoplasia and for cervical cancer. The organized programmes define the ages and the frequencies of screening and they use personal invitations with times and places for screening and the programme gives personal information of the results of screening even when the smear is negative.
In Finland the organization of the mass screenings was initiated by the Cancer Society of Finland in the mid·1960s. The women to be screened are chosen by , in Finland , in Iceland , in Norway and in Sweden . Data from Nordic Cancer Registries 16 incidence for all age groups from 30-34 to 50-54 between the 1950s and the 1980s was about 70%. At younger and older age groups the changes were smaller. The trends in mortality from cervical cancer have decreased correspondingly, at a lower level, both for the total risk and for all the age groups up to 50-54 years.
Between the Nordic countries there was a strong correlation between the extent of the organized screening programme and changes in the risk of cervical cancer (Figure 2 ). The reduction in the risk was steepest in Iceland, Finland and Sweden, intermediate in Denmark. In Norway the incidence rates of cervical cancer increased up to the late 1970s. An analysis by Liiiirii et at. 2 on the mortality trends for cervical cancer in the Nordic countries confirmed the results based on new cases of cancer.
The age-specific trends of both incidence" and mortality'' indicate that the target age range of a programme is a more important determinant of risk reduction than the frequency of screening within the defined range of 2-5 years and age range of 30-60. This agrees with the estimates of the IARC working group9,lO that the protective effect of screening after a negative smear is high for screening intervals of up to 5 years (over 80%).
Proposals for programme modifications
Recent data originating from different populations indicate an increase of preclinical lesions at young ages ll -13 • This increase was related to changes in sexual mores allowing the spread of, for example, human papillomavirus infections rather than to an increase in smear taking activity or changes in diagnostic criteria. The increase has led to proposals to start and to intensify screening at young ages. The prevalence rates in Finland of dysplasias detected at organized screening are known. There is some overall increase in the rates which is not especially predominant at young ages, however.
Some increase has been reported in the invasive disease as well 14 ,15 . In the Nordic countries there is very little evidence for such an increase'", The purpose of screening for cervical cancer is to prevent invasive disease, and it is sufficient to start screening a few years before invasive disease appears. Frankly invasive cervical cancer is rare under the age of 30 years and deaths from cervical cancer occur infrequently at ages under 35 years. Thus the cost
Conclusion
It seems clear that spontaneous screening for cervical cancer covers a relatively limited and selected proportion of the population with repeated screening at short intervals but does not catch the population who really would benefit from regular screening for cervical cancer 1B -20 • The experience of the Nordic countries shows that a population-based and well organized screening programme with a sufficiently wide target age range can be more successful in this respect 2 ,B and thus effective in reducing both the incidence of and the mortality from invasive cervical cancer.
Iceland and Finland are probably the countries with the largest reduction in the incidence of cervical cancer due to screening. In Finland the reduction has been more than 60%. In Denmark, Sweden, parts of Canada, German Democratic Republic, Scotland and the United States there has been a moderate to substantial reduction in incidence. The reduction in risk closely correlates with the degree of organization. In many countries where there has been a substantial effect, the screening programme has consumed relatively few resources -for example, in Finland the official recommendation to start the screening programme at 30 years and to repeat the smear every 5 years has resulted in one of the biggest reductions in the risk of cervical cancer reported anywhere. effectiveness of screening remains low if rare occurrences ofthe disease are found by screening, and there is no good evidence for screening age groups, for example, under 25 years for cervical cancer. Viral infections which are supposed to increase the risk of cervical cancer occur at ages younger than 25. If identifying and treating them prevents spread, there is motivation to screen for papillomavirus and other infections, even if it is likely that the long-term adverse effects, such as invasive cancer, could be prevented later in life when many of the original lesions have spontaneously regressed. Screening for viral infections should not be identified with screening for cancer, however.
To reduce costs selective screening of high risk groups have been proposed. The screening programme itself provides data on risk factors related to cervical cancer. Independently whether the selective screening should be based on single risk factor or on a combination of them it seems that the programme sensitivity to identify preinvasive lesions in total target population remains IOW 17 -ie if the high risk group is small enough to result in a substantial reduction in cost, then the cases in the target population belonging to the low risk group not subjected to screening are too numerous. Age as a risk indicator is an important exception and all screening programmes define the target population at high risk by age. 
